T1	Participants 226 263	patients with vascular dementia (VaD)
T2	Participants 432 621	Patients (n=603; mean age, 73.9 years; 55.2% men) with probable (70.5%) or possible (29.5%) VaD, according to criteria of the National Institute of Neurological Disorders and Stroke (NINDS)
T3	Participants 944 960	donepezil groups
T4	Participants 1012 1046	placebo on the Alzheimer's Disease
